Mohammed Qatanani
Director Técnico/Científico/I+D en SCHOLAR ROCK HOLDING CORPORATION .
Fortuna: 1 M $ al 31/05/2024
Cargos activos de Mohammed Qatanani
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Director Técnico/Científico/I+D | 01/09/2022 | - |
Historial de carrera de Mohammed Qatanani
Antiguos cargos conocidos de Mohammed Qatanani.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/02/2018 | 01/09/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2015 | 01/01/2018 |
Formación de Mohammed Qatanani.
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Líbano | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Empresas privadas | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Mohammed Qatanani
- Experiencia
